Merlintrader’s Daily Briefing

Tuesday, July 28, 2026 — the oil trade and the artificial-intelligence trade have separated. Monday’s New York session closed with the Dow up more than 260 points on cheaper crude while the Nasdaq slipped again, and overnight that split turned violent in Asia: South Korea’s Kospi fell about 10% and tripped a circuit breaker, Tokyo lost more than 4%, and the selling ran through every memory and chip-equipment name on the board. The trigger was a report that a Chinese firm has begun mass production of a chipmaking technology long held by a handful of foreign suppliers, layered on top of three days of questions about how Nvidia is financing its own customers. The Federal Reserve begins a two-day meeting today, with the decision Wednesday afternoon.

Where Wall Street closed on Monday
  • Indices — The Dow Jones Industrial Average rose 0.51%, or 262.83 points, to 52,210.08. The S&P 500 added 0.02% to 7,413.18. The Nasdaq Composite fell 0.18% to 24,932.08. Three indices, three different messages, one cause.Indices
  • Semiconductors — The VanEck Semiconductor ETF closed at $548.55 against $561.19 on Friday, a decline of about 2.3% and a third consecutive down session. The complex has now given back the whole of its July advance.Chips
  • Nvidia — Shares closed at $196.51 against $206.84, a fall of about 5.0%, on volume of roughly 154 million shares. The stock traded as low as $195.44 during the session and has lost its position as the largest listed company.AI
  • Apple — Shares closed at $336.91, up about 1.2%, and reclaimed the title of the world’s most valuable listed company. The rotation is not a judgement on Apple’s quarter, which arrives Thursday; it is a judgement on the certainty attached to everyone else’s.Big Tech
  • Micron — The memory maker closed at $900.20, down about 2.3%, extending Friday’s decline. Memory is where the Chinese supply story bites first, and the tape is treating it accordingly.Chips
The chip rout goes global overnight
  • Seoul — The Kospi fell about 10% and the exchange triggered a circuit breaker after an 8% drop, suspending index and programme trading for twenty minutes. SK Hynix lost roughly 11% and Samsung Electronics about 9%; the Kosdaq fell about 6.5%.Asia
  • Tokyo and Taipei — The Nikkei 225 dropped more than 4%, with Kioxia down about 18% and Advantest and Tokyo Electron each down around 11%. Taipei fell more than 4% as Taiwan Semiconductor Manufacturing declined. Hong Kong was close to unchanged.Asia
  • The trigger — The Information reported that China’s Shanghai Yuliangsheng has begun mass production of a chipmaking technology that had been dominated by a small group of established suppliers. Equipment and memory names carry the first-order exposure to that claim.Chips
  • The other half — The report landed on a market already unwinding the circular-financing question around Nvidia: guaranteeing customer debt, financing customer chip purchases, and taking equity in customers. Supply competition and demand financing are separate worries that arrived together.AI
  • Scale — Asian equities are now roughly 10% below their June peak, the technical definition of a correction for the regional benchmark. SK Hynix reports Wednesday, its first set of results since listing in New York.Asia
  • US futures — Ahead of the opening bell, S&P 500 futures were down about 0.1% and Nasdaq 100 futures about 0.5%, while Dow futures were marginally higher. The American tape is not fully importing the Asian move.Futures
Oil, rates and the peace premium
  • Crude — West Texas Intermediate settled around $82.62 a barrel, down about 8.7% on the day, and Brent around $90.28, down about 8.2%, as the pause in United States strikes on Iran held and work resumed on restarting negotiations.Energy
  • Treasuries — The 10-year yield eased to roughly 4.65% as the oil decline took pressure off the near-term inflation path. Last week the same yield reached its highest level since January 2025 on the opposite impulse.Rates
  • The asymmetry — A pause is not a settlement. The barrels never stopped flowing during the strikes; what has moved twice in two weeks is the probability the market attaches to their stopping. That probability can be repriced again in either direction.Energy
  • Fuel-sensitive names — American Airlines closed up about 3.3% and Carnival about 3.0%, the clearest expression of the cheaper-crude trade. Industrials and travel carried Monday’s Dow advance while technology subtracted from it.Markets
Biotech: the extremes stayed wide
  • Capricor — Shares closed at $6.99, down about 64% on the day and on volume near 30 million, after the agency briefing document for tomorrow’s advisory committee questioned whether the deramiocel study met its pre-specified endpoints. The company published a response arguing its results follow the final analysis plan agreed before unblinding.Biotech
  • What happens Wednesday — The Cellular, Tissue and Gene Therapies Advisory Committee meets on the deramiocel application in Duchenne muscular dystrophy. The vote is advisory and non-binding; the agency’s own action date on the file is 22 August.FDA
  • Omeros — Shares closed at $11.34, up about 15.8%, after AstraZeneca reported that Ultomiris missed its primary endpoint of event-free survival at 26 weeks in a Phase 3 study in a related rare condition. Omeros markets Yartemlea, approved for transplant-associated thrombotic microangiopathy.Biotech
  • Outlook Therapeutics — Shares closed at $1.07, down about 24% on very heavy volume, giving back a large part of the move that followed the 24 July clearance of LYTENAVA in wet age-related macular degeneration. The approval arrived two business days before the scheduled action date.Biotech
  • Johnson & Johnson — The company offered up to $5.5 billion to settle outstanding talc litigation, a figure that puts a number on a liability the market has been estimating for years.Pharma
Merlintrader watchlist, Monday’s closes
  • Palantir — Closed at $131.53, up 7.0% on volume near 37 million, after Oppenheimer reaffirmed an Outperform rating and a $200 price target ahead of second-quarter results, which are due on 3 August after the close.AI
  • Space and defence — Rocket Lab closed at $66.94, up 4.7%; AST SpaceMobile at $58.29, up 3.7%; Unusual Machines at $20.60, up 6.4%; Castellum at $0.67, up 7.6%; Ondas at $8.02, up 2.8% on volume above 66 million.Space
  • Small-cap AI — SoundHound closed at $6.41, up 4.1%; BigBear.ai at $2.83, up 2.5%; Palladyne AI at $5.17, up 4.7%; C3.ai at $8.82, up 8.2%; POET Technologies at $7.09, up 2.9%.AI
  • Energy and biotech names — Oklo closed at $41.81, up 3.9%. Geron closed at $1.48, up 4.2%. SELLAS closed at $10.84, down 4.3%. Eton at $42.31 and Vera at $35.18 were both marginally lower.Watchlist
  • Low-float warning — T3 Defense closed up about 201% at $13.10 on volume near 79 million. The company completed a one-for-125 reverse split that cut the public share count to roughly 1.1 million shares. A float that small can move on order flow alone.Micro-cap
What lands today and this week
  • The Fed — The Federal Open Market Committee begins its two-day meeting today. The statement comes Wednesday at 2:00 p.m. Eastern with the press conference at 2:30. This is one of the four meetings of the year without an updated projection summary; the next dot plot is September.Macro
  • Consumer confidence — The Conference Board’s July reading is published at 10:00 a.m. Eastern, the first survey-based look at how households absorbed two weeks of triple-digit crude before the pause.Macro
  • Earnings before the open — Boeing, Coca-Cola, UPS, PayPal, S&P Global, Royal Caribbean and Hilton report this morning. Boeing consensus points to a small per-share loss on revenue near $24 billion; UPS is the cleanest read on freight volumes in the set.Earnings
  • The megacaps — Microsoft and Meta report Wednesday after the close, Apple and Amazon on Thursday. Four of the largest capital-expenditure budgets in the world will be updated inside forty-eight hours, into a tape that has spent three days doubting how that spending is funded.Earnings
  • Friday — The June personal consumption expenditures price index and the second-quarter employment cost index close the week, alongside a Bank of Japan decision and euro-area inflation.Macro
Bottom line
  • Two stories, one tape — Cheaper oil is a genuine easing of the inflation constraint, and it is why the Dow rose and yields fell. It does nothing to answer whether the memory cycle faces a new low-cost competitor or whether the AI buildout is being financed by its own supplier. Those questions get their first hard data on Wednesday and Thursday.Analysis
  • Educational content — Nothing here is a recommendation to buy or sell any security. Prices and levels reflect the most recent verified prints available at the time of writing and change continuously.Disclaimer
Read the full Daily Briefing

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: July 15 → September 30, 2026. Compact homepage board for FDA decisions, advisory committees, regulatory submissions and major clinical readouts. October and later events are excluded from this widget.

38Active
20FDA / Reg
18Data / Filing
Jul 27Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$NRXPKETAFREEJul 29GDUFA Preservative-free IV ketamine

NRx Pharmaceuticals. FDA-assigned GDUFA goal date for the KETAFREE ANDA, a preservative-free intravenous ketamine formulation. This is a generic-drug decision, not a PDUFA for NRX-100 or NRX-101; the KETAFREE proprietary name remains subject to FDA review.

$CAPRderamiocel panelJul 29AdCom Panel before Aug PDUFA

Capricor. FDA advisory committee for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Panel tone and briefing documents are the key pre-PDUFA read-through.

$VTRSMR-100A-01Jul 30PDUFA Low-dose estrogen weekly contraceptive patch

Viatris. FDA target action date for the 505(b)(2) NDA for the investigational low-dose estrogen combined hormonal contraceptive weekly patch. Supported by the Phase 3 Luminous study, NCT05139121.

$REPLRP1 panelJul 30AdCom Melanoma panel review

Replimune. FDA advisory committee for RP1 plus nivolumab in advanced melanoma after anti-PD-1 therapy. Single-arm evidence risk remains central.

$REPLRP1Aug 2PDUFA Melanoma BLA resubmission

Replimune. BLA resubmission goal date for RP1. This is a very compressed AdCom-to-PDUFA setup with elevated regulatory risk.

$MRNAmFLUSIVAAug 5PDUFA mRNA seasonal flu

Moderna. BLA PDUFA for mRNA seasonal flu vaccine candidate in adults 50+. More platform and lifecycle read-through than pure small-cap binary.

$REGNgaretosmabAugFDA FOP ultra-rare disease

Regeneron. BLA target action month for garetosmab in adult fibrodysplasia ossificans progressiva. Month-only calendar item.

$LNTHMK-6240Aug 13NDA Tau PET imaging

Lantheus. NDA PDUFA for MK-6240 tau PET imaging in Alzheimer’s disease. Diagnostic/imaging catalyst, not a therapeutic efficacy binary.

$CAPRderamiocelAug 22PDUFA DMD cardiomyopathy

Capricor. BLA PDUFA for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Prior CRL history and July AdCom make this highly binary.

$RAREDTX401Aug 23BLA GSDIa gene therapy

Ultragenyx. Priority Review BLA PDUFA for DTX401 in glycogen storage disease type Ia. First of two near-term Ultragenyx gene-therapy decisions.

$BIIBLeqembi IQLIKAug 24sBLA SC starting dose

Biogen / Eisai. sBLA PDUFA for once-weekly subcutaneous Leqembi starting-dose use. Large-cap Alzheimer’s lifecycle catalyst.

$JAZZZiihera comboAug 25sBLA 1L HER2+ GEA

Jazz Pharmaceuticals. sBLA PDUFA for Ziihera combination use in first-line HER2-positive gastroesophageal adenocarcinoma.

$GILDBIC/LENAug 27NDA Once-daily HIV regimen

Gilead. NDA PDUFA for bictegravir/lenacapavir in virologically suppressed adults. Strategic HIV franchise catalyst.

$PTGXrusfertideQ3PDUFA Polycythemia vera

Protagonist / Takeda. Priority Review NDA window for rusfertide in polycythemia vera. Exact date not pinned in this compact board.

$NUVLzidesamtinibSep 18NDA ROS1+ NSCLC

Nuvalent. NDA PDUFA for zidesamtinib in ROS1-positive non-small-cell lung cancer. Important targeted-oncology regulatory event.

$RAREUX111Sep 19Risk Sanfilippo A gene therapy

Ultragenyx. Resubmitted BLA PDUFA for UX111 in Sanfilippo syndrome type A. CMC and facility risk remain the key swing factors.

$IONSzilganersenSep 22NDA Alexander disease

Ionis. NDA PDUFA for zilganersen in Alexander disease. Rare neurological disease Priority Review event.

$BFRIAmeluz PDTSep 28sNDA Superficial BCC expansion

Biofrontera. PDUFA for Ameluz photodynamic therapy sNDA seeking expansion into superficial basal cell carcinoma. Small-cap liquidity can amplify reaction.

$SRRKapitegromabSep 30BLA Spinal muscular atrophy

Scholar Rock. BLA PDUFA for apitegromab in spinal muscular atrophy. Manufacturing and fill-finish facility status remain key watch items.

$ROIVbrepocitinibQ3NDA Dermatomyositis

Priovant / Roivant. NDA Priority Review window for brepocitinib in dermatomyositis. Company has pointed to potential launch timing by end-September if approved.

$QUREAMT-130Q3BLA Huntington’s AA path

uniQure. Planned BLA submission for AMT-130 in Huntington’s disease. Not a PDUFA, but one of the most important regulatory-pathway events in the quarter.

$SLNdivesiranAugData SANRECO Phase 2 PV

Silence Therapeutics. SANRECO Phase 2 topline data for divesiran in polycythemia vera. Important read-through alongside $PTGX / Takeda rusfertide.

$IMMXNXC-201Q3Data AL amyloidosis

Immix Biopharma. NEXICART-2 topline data for NXC-201 in relapsed/refractory AL amyloidosis. BLA-enabling study, high-volatility small-cap setup.

$KPTIselinexorNearData Endometrial cancer Ph3

Karyopharm. XPORT-EC-042 Phase 3 topline data for selinexor in endometrial cancer. Treat as near-term until released or formally delayed.

$KODDAYBREAKQ3Data Wet AMD Phase 3

Kodiak Sciences. DAYBREAK Phase 3 topline data for tarcocimab / KSI-501 in wet AMD. Watch efficacy, durability, dosing interval and safety.

$ALMSenvudeucitinibQ3Data SLE Phase 2b

Alumis. LUMUS Phase 2b readout for envudeucitinib in systemic lupus erythematosus. Autoimmune data can be noisy; dose response matters.

$IVVDVYD2311Q3Data DECLARATION pivotal

Invivyd. DECLARATION pivotal / Phase 3 topline data for VYD2311. COVID-antibody sentiment can be unstable, but pivotal data can still move the name.

$MPLTML-007C-MAMid-AugData ZEPHYR schizophrenia Ph2

MapLight Therapeutics. Phase 2 ZEPHYR topline results for ML-007C-MA in schizophrenia. CNS readout with potentially sharp binary reaction.

$AMLXavexitideQ3Ph3 PBH pivotal LUCIDITY

Amylyx. Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia. One of the clearest Phase 3 clinical binaries of the quarter.

$PHVSdeucrictibant ERQ3Ph3 HAE prophylaxis Ph3

Pharvaris. Phase 3 CHAPTER-3 data for extended-release deucrictibant as prophylaxis for hereditary angioedema. Major HAE readout.

$SYRESPY003Q3Data IBD / UC Phase 2

Spyre Therapeutics. Phase 2 SKYLINE Part A topline data for SPY003 in inflammatory bowel disease and ulcerative colitis.

$VERATrutakna / ataciceptQ3eGFR ORIGIN 3 follow-up

Vera Therapeutics. ORIGIN 3 eGFR analysis following accelerated approval. Not another approval decision, but important for durability and confirmatory confidence.

$OCGNOCU410STQ3Data Stargardt interim analysis

Ocugen. Interim OCU410ST analysis after 24 patients complete eight months of follow-up in Stargardt disease. Small-cap ophthalmology catalyst.

$XENEazetukalnerQ3NDA Focal-onset seizures filing

Xenon. Expected NDA submission for azetukalner in focal-onset seizures. Filing confirmation would set up future FDA acceptance and PDUFA timing.

$BBIOinfigratinibQ3NDA Achondroplasia filing

BridgeBio. Expected NDA submission for infigratinib in achondroplasia. Submission timing and acceptance will define the next regulatory leg.

$CLNNCNM-Au8Q3NDA ALS accelerated pathway

Clene. Targeted NDA submission for CNM-Au8 in ALS through an accelerated pathway. Very high regulatory strategy risk because submission does not guarantee acceptance.

$OCGNOCU400Q3BLA Rolling BLA start

Ocugen. Expected start of rolling BLA submission for OCU400 in retinitis pigmentosa. Filing progress, manufacturing and future acceptance are the next watch items.

$MLTXsonelokimabLate SepBLA HS filing watch

MoonLake. Planned BLA submission for sonelokimab in hidradenitis suppurativa around the end of September. Acceptance would create the next formal FDA calendar item.

Most attention-worthy watchlist

$NRXP$REPL$CAPR$RARE$NUVL$IONS$SRRK$AMLX$PHVS$QURE$MPLT

Board rule

Only July–September catalysts are shown. October and later events are intentionally excluded from this compact homepage widget. Resolved decisions are removed from the active board: $CELC Revtorpyk / gedatolisib was approved by the FDA on July 14, ahead of its July 17 PDUFA date, with the U.S. commercial launch expected in Q3 2026; $SNY Sarclisa SC was approved on July 10, ahead of its original July 23 target date. Events with only Q3 guidance are included, but should be rechecked against company filings before trading around them.

Educational content only — not investment advice. Verify dates and filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with CONSOB (Italy) and SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.

Avvertenza. Questo contenuto ha finalità esclusivamente didattiche e informative. Non costituisce consulenza finanziaria né una raccomandazione di acquisto o vendita di alcun titolo, in linea con le indicazioni CONSOB (Italia) e SEC (USA). I dati sono generati dall'AI a partire da fonti web e possono contenere errori o non essere aggiornati — verifica sempre rispetto alla fonte primaria collegata. Fai le tue ricerche e consulta un consulente autorizzato. Disclaimer completo: merlintrader.com/disclaimer.